Table 1. SUV_peak values, T/L ratios of the peak tumor to mean liver SUV and correlation of visual PET results and immunoreactive scores (IRS) for SSTR2a and SSTR5.

Patient	PET	SUVpeak	T/L	SSTR2-IRS	SSTR5-IRS
1	negative	6.0	0.4	0	0
2	positive	23.3	2.7	9	0
3	intermediate	9.2	1.8	1	0
4	negative	7.2	0.8	N/A	N/A
5	intermediate	10.8	1.1	0	4
6	positive	32.5	4.8	8	0
7	intermediate	14.2	1.3	0	0
8	intermediate	9.1	1.4	8	2
9	positive	35.3	4.5	12	0
10	positive	20.5	2.7	12	2
11	negative	6.2	1.0	0	0
12	intermediate	8.5	1.6	0	0
13	negative	3.6	0.6	2	0
14	negative	4.8	0.8	0	0
15	negative	3.3	0.4	0	0
16	negative	5.4	0.8	0	0
17	intermediate	7.0	0.9	0	0
18	negative	3.9	0.4	1	0
19	negative	2.5	0.4	0	0
20	negative	2.8	0.8	1	0
21	negative	4.9	0.5	N/A	N/A

For quantification of SSTR-positivity at PET, the categories “positive” (all tumor lesions PET-positive with ⁶⁸Ga-DOTATATE uptake > liver), “intermediate” (the majority of lesions positive) and “negative” (the majority of / all tumor lesions PET-negative) are used. The IRS score is given for histologically assessed SSTR2a/5 expression.